Introduction
============

It has become increasingly accepted that self-reports from cancer patients provide exclusive perspectives and address aspects of wellbeing, feelings, and functioning which may not otherwise be captured by standard clinical assessments \[[@b1-crt-2018-426]\]. Therefore, patient-reported outcome, specifically health-related quality of life (HRQOL), is considered an important outcome measure in cancer clinical trials \[[@b2-crt-2018-426]\] and shows consistency and reliability in association with clinical outcomes in both oncology and non-oncology fields \[[@b3-crt-2018-426],[@b4-crt-2018-426]\]. Assessing quality of life (QOL) in cancer patients could improve treatment and be used as a medical prognostic factor for survival \[[@b5-crt-2018-426]-[@b8-crt-2018-426]\]. Results from QOL studies can further recommend the direction needed for more efficient treatment for cancer patients \[[@b9-crt-2018-426]\].

Previous studies measuring HRQOL focused on comparing patients' HRQOL between different treatments or measuring the longitudinal impact of treatment on HRQOL at different treatment phases. However, interests have shifted to finding the relationship between HRQOL and survival since data in the literature show that HRQOL predicts survival in different types of cancers independent of other clinical factors \[[@b2-crt-2018-426],[@b10-crt-2018-426],[@b11-crt-2018-426]\]. The number of studies reporting the relationship between HRQOL and survival of breast cancer (BC) patients is limited \[[@b12-crt-2018-426]\]. The most common study design was by randomized controlled trials \[[@b9-crt-2018-426],[@b11-crt-2018-426],[@b13-crt-2018-426]-[@b17-crt-2018-426]\]; two studies followed a cohort design \[[@b18-crt-2018-426],[@b19-crt-2018-426]\], and two were systematic reviews and meta-analyses \[[@b1-crt-2018-426],[@b20-crt-2018-426]\]. These studies utilized the baseline QOL, which was usually measured a few days to two weeks before treatment, and its association with survival of BC patients. Results from these studies, however, were inconsistent. Some reported that baseline QOL provided useful prognostic information \[[@b13-crt-2018-426],[@b19-crt-2018-426]\]; others, conversely, reported that baseline QOL had no great importance in predicting primary clinical endpoints, including overall survival (OS) \[[@b11-crt-2018-426],[@b16-crt-2018-426]\]. Other studies reported that QOL scores predicted outcome in metastatic \[[@b21-crt-2018-426]\] but not in early BC \[[@b14-crt-2018-426]\].

The relationship between HRQOL outcomes, symptoms, and long-term survival have not been completely elucidated \[[@b9-crt-2018-426]\]. From previous studies, baseline QOL might not be a prognostic factor, especially for non-metastatic BC patients. Due to the inconsistency of previous studies, we shifted our interest to the QOL measured one year after patients were diagnosed, with the hypothesis that the patients' QOL status at this time point has better prognostic value for OS. Using the BC cancer cohort data at the National Cancer Center (NCC) of Korea, we evaluated the association between 1-year post-diagnosis HRQOL and OS, with adjustment for QOL status at baseline.

Thus, we explored which dimensions of HRQOL after patients finished treatment would be useful to predict their survival. To our knowledge, this is one of the few studies evaluating the prognostic significance of HRQOL measured at this specific time point with a long-term follow-up period. Our results might further evidence on utilizing HRQOL as a survival prognostic factor.

Materials and Methods
=====================

1. Study design and subject recruitment
---------------------------------------

In May 2004, a BC prospective cohort was set up to collect data on issues of cancer survivorship at the NCC in Korea. Among 371 patients diagnosed between May 2004 and September 2006, 299 agreed to participate in our cohort study ([Fig. 1](#f1-crt-2018-426){ref-type="fig"}). Eligibility criteria were histologically confirmed invasive cancer (stage I-IV), being 18 years or older, and absence of other cancers. Participants were prospectively followed up according to the study protocol. More details on patients' recruitments elsewhere \[[@b22-crt-2018-426],[@b23-crt-2018-426]\].

2. Data collection
------------------

BC patients were diagnosed by oncologists at the Breast Cancer Department of NCC hospital. We explained the purpose and protocol of the study to all participants. The survey was based on self-reported data. The first data collection was conducted a few days after diagnosis. After the interview, subjects were given a baseline questionnaire together with a stamped and addressed return envelope. One year after diagnosis, each participant was sent a letter with a follow-up questionnaire, a stamped and addressed return envelope. Those who did not return the questionnaire within 2 weeks were contacted by phone up to three times. Data on survival were obtained through linkage with the national death registration database, with the last data collection done in July 2018.

3. Measures
-----------

### 1) Sociodemographic and clinical characteristics

Age at diagnosis and level of education were measured one time at baseline. Other sociodemographic characteristics, including religious beliefs, job status, monthly household income, and marital status were measured at both baseline and 1-year post-diagnosis. Data on comorbidity status and health behaviors (cigarette smoking and alcohol drinking) were also collected at both measures. In the current study, we presented the results measured at 1-year post-diagnosis for these variables. Medical information obtained from the NCC hospital electronic medical records included stage at diagnosis, radiotherapy (yes or no), duration of chemotherapy (days), chemotherapy (yes or no), duration of chemotherapy (days), hormone therapy (yes or no), and BC subtype. Stage at diagnosis was categorized into two groups: stage I to IIA and stage IIB to IV. BC subtype variable has four values: estrogen receptor (ER)/progesterone receptor (PR) positive and human epidermal growth factor receptor (HER2) positive; ER/PR positive and HER2 negative; ER/PR negative and HER2 positive; ER/PR negative and HER2 negative.

### 2) Health-related quality of life

HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) general module QLQ-C30 \[[@b24-crt-2018-426]\] and BC module QLQ-BR23 \[[@b25-crt-2018-426]\]. These are well-validated and commonly utilized instruments in the oncology field \[[@b2-crt-2018-426],[@b26-crt-2018-426]\]. EORTC QLQ-C30 assesses a patient's capacity to fulfill the activities of daily living, comprising of five functional scales, six single symptom items, and a global health status scale. The QLQ BR-23 module incorporates multi-item and single item scales to assess systemic therapy side effects, breast symptoms, and other BC QOL scales. In both instruments, higher functional scores and higher global health status represent better functioning and QOL whereas a higher symptom score indicates more severe symptoms or worse QOL. The Korean versions of both instruments were validated in previous research. Cronbach's alpha was greater than 0.7 for the Korean validated version of both instruments \[[@b27-crt-2018-426],[@b28-crt-2018-426]\]. HRQOL assessments were performed at two-time points: immediately after diagnosis (baseline) and 1-year post-diagnosis.

### 3) Data analysis and statistical methods

Demographic characteristics and clinical factors were summarized using frequencies and percentages for categorical variables, and means and their standard deviations or medians and their interquartile ranges for continuous variables, with stratification by survival status. Statistical significance of differences between groups in categorical variables were tested by Fisher exact test. The normality of the distribution of continuous variables was tested by the Shapiro-Wilk test. Statistical significance of differences between groups in continuous variables was tested by the Student's t test for normally distributed variables and the Kruskal-Wallis test for non-normally distributed variables. Statistical significance of differences in QOL scores between baseline and 1-year postdiagnosis was tested by non-parametric Wilco-xon signed-rank test.

Patient survival was defined as the time interval between the date of BC diagnosis to the date of death from any cause or the date of the last follow-up. Demographic, clinical and QOL variables were evaluated using univariate Cox proportional hazards models. In all multivariate models, age at diagnosis, stage at diagnosis, and baseline HRQOL were adjusted. For other factors, backward model selection was performed to choose variables to be included in the multivariate model. For each HRQOL scale from QLQ-C30 and QLQ-BR23, we fitted a Cox model; with survival status as the response variable, the main predictor variable was HRQOL score.

For HRQOL variables, the raw scores were linearly transformed to give standard scores in the range of 0-100 for each of the functional and symptom scales according to the EORTC scoring manual \[[@b29-crt-2018-426]\]. A difference of 5-10 points in QOL scores represents a small change, 10-20 points a moderate change and greater than 20 points a large, clinically significant change from the patient's perspective. In the current study, we presented hazard ratios (HR) for a 10-point change on the continuous HRQOL variables \[[@b20-crt-2018-426],[@b30-crt-2018-426]\]. All tests were two-sided; p-values less than 0.05 were considered statistically significant. Statistical analyses were conducted using SAS statistical software ver. 9.2 (SAS Institute Inc., Cary, NC) and figures were visualized in R Studio Software R ver. 3.5.1, 2018 (The R Foundation for Statistical Computing Platform, Vienna, Austria).

4. Ethical statement
--------------------

The protocol and follow-up of this study were approved by the NCC Institutional Review Board (NCCNCS-04-034). All patients provided written informed consent prior to participation.

Results
=======

1. Patient characteristics
--------------------------

Among 371 women diagnosed with BC at the NCC, 299 agreed to participate in our study (80.6%) and their baseline HRQOL was measured. Of these, 206 patients replied at 1-year post-diagnosis. Of the 206 patients, 32 deaths were reported as at July 2018. The follow-up period was 11.6 years on average with a 5-year OS rate of 93.2% and a 10-year rate of 87.7% ([Fig. 1](#f1-crt-2018-426){ref-type="fig"}). [Table 1](#t1-crt-2018-426){ref-type="table"} describes demographic and clinical characteristics, classified according to survival status. Mean age was 47.3±9.1 at diagnosis, 79.0% had radiotherapy and 86.3% had chemotherapy. Notably, all deaths in our cohort had chemotherapy. Comorbidity status and stage at diagnosis were significantly different between the survivor and death groups. In death group, 51.7% had at least one comorbidity versus 30.9% in survivor groups. In addition, in death group, 68.8% were diagnosed at stage IIB to IV compared to 30.5% in survivor group. These features in the survivor group were 27.0% and 30.5% respectively.

2. HRQOL at baseline and 1-year post-diagnosis
----------------------------------------------

[Table 2](#t2-crt-2018-426){ref-type="table"} displays HRQOL scores at baseline and 1-year post-diagnosis by survival status for all scales of QOL-C30 and QLQ-BR23. The global health status mean score of the cohort at 1-year post-diagnosis was 66.1±1.4. Among the functional scales, at 1-year post-diagnosis the social scale had the lowest mean score (71.1±1.9) while the physical scale had the highest mean score (76.0±1.1). In both the survivor and death groups, QOL deteriorated at 1-year post-diagnosis compared to baseline, with an increase in the symptom scales and decrease in the functional scales. However, compared to the survivor group, the differences in the death group were greater in several scales. For example, the difference was 6.2 points (p \< 0.001) in the physical scale of the survivor group while it was 15.5 points (p \< 0.001) in the death group.

[Figs. 2](#f2-crt-2018-426){ref-type="fig"}, [3](#f3-crt-2018-426){ref-type="fig"}, and [4](#f4-crt-2018-426){ref-type="fig"} illustrate the trend of HRQOL, measured by EORTC QLQ-C30, and QLQ-BR23 respectively, from baseline to 1-year post-diagnosis in survivors and deaths. At baseline, QOL scores of both survivors and deaths were similar while at 1-year post-diagnosis, there existed larger differences between these two groups. The survivor group had a significantly better QOL at 1-year post-diagnosis in most scales. A large difference in the QOL score between survivors and deaths was observed in several scales, including role (13.9, p=0.004), fatigue (13.6, p=0.001), dyspnea (12.4, p=0.022), and financial difficulties (13.8, p=0.007) (data not shown).

3. Survival analysis
--------------------

Univariate and multivariate Cox regression analyses for each QOL variable are displayed in [Table 3](#t3-crt-2018-426){ref-type="table"}. HR in all models corresponded to a 10-point increment for HRQOL scores. From the adjusted model, higher scores in the physical (adjusted HR \[aHR\], 0.70; p=0.029), role (aHR, 0.68; p=0.001), emotional (aHR, 0.72; p=0.012) scales significantly improved survival. In contrast, higher scores in fatigue (aHR, 1.34; p=0.006), dyspnea (aHR, 1.29; p=0.009), and appetite loss (aHR, 1.24; p=0.036) increased risk of death. In addition, marginally significant associations were found between global health status and future perspective scales with OS (aHR, 0.77 and 0.83, respectively). Results were interpreted as such: for example, with the fatigue scale, a 10-point increase in fatigue score was associated with 1.34 times increased risk of death.

Discussion
==========

Utilizing 1-year post-diagnosis QOL and long-term survival are two strengths exclusive to our study. While previous studies focused on correlating pretreatment QOL with survival, we shifted our interest to post-treatment QOL. In this study, the majority of our BC patients were diagnosed at stage I to III and finished their treatment as well as recovery within seven to eight months. One year after diagnosis, all participants had finished their treatment and had a few months for recovery. Given that cancer treatments have negative physical and socio-emotional consequences, assessing the patients' QOL at this time and how these QOL associated with survival are of great importance. To the best of our knowledge, this approach has not been utilized in published works and is therefore a unique aspect of this study. An additional strength of this study was the long-term follow-up, with the median follow-up time being more than ten years.

There are two key findings from our study. Firstly, at 1-year post-diagnosis, survivors had better HRQOL scores compared to deaths even though their health status was similar at baseline. Secondly, we found that at 1-year post-diagnosis, functional scales, including physical, role, emotional, and symptom scales, including fatigue, dyspnea were predictive for OS. HRQOL is considered one of the main study endpoints in the oncology field and provides useful prognostic information to both patients and health care providers. However, it continues to be evaluated infrequently in clinical oncology practices because of many challenges and barriers \[[@b31-crt-2018-426]\]. These barriers are not due to the lack of valid tools for measurement but are due to the difficulty in incorporating QOL measurements into busy clinical practices \[[@b32-crt-2018-426]\]. Here, there was a statistically significant relationship between several dimensions of QOL and long-term survival in BC patients. Thus, our results support the rationale to incorporate regular QOL assessment and management into oncological practices.

HRQOL at 1-year post-diagnosis of BC patients in this cohort was investigated in a previous publication by Lee et al. \[[@b22-crt-2018-426]\]. The authors evaluated the HRQOL status and compared the results with that of the general population. Their findings suggested that the improvement in HRQOL scores seen at 1 year after diagnosis was modest and did not reach the level of the general population \[[@b22-crt-2018-426]\]. Here, we re-evaluated the HRQOL scores at this time point but shifted our emphasis to the difference between the survivor and death groups. In QLQ-C30, the role function was measured by two questions which assessed the degree of impairment of work or daily activities and leisure-related activities. We found that the role function of patients after completing the treatment course was predictive of survival independent of disease stage, the status of the patient at baseline and other factors. Our findings for the role function scale was in line with previous studies using baseline QOL scores as predictors for survival \[[@b5-crt-2018-426],[@b21-crt-2018-426]\]. Previous studies also found that fatigue was a significant predictive factor for survival, together with pain or global QOL scale. However, HRQOL was measured at baseline, not post-treatment as in this study \[[@b5-crt-2018-426],[@b11-crt-2018-426],[@b17-crt-2018-426],[@b21-crt-2018-426]\]. Our findings showed that emotional function was an independent prognostic indicator of OS. Consistent results were found in previous studies. Anxious emotion has previously been associated with poor survival in advanced cancer patients \[[@b33-crt-2018-426]\]. Our results add more evidences to support that interventions to improve emotional and stress management might have a positive impact on survival.

Besides the medical-related QOL scales discussed above, our findings suggest that at 1-year post-diagnosis, non-medical issues may be predictive for survival. Patients who reported more worries, depression or concerns about their future health and body image might have poorer survival, regardless of their baseline QOL status and stage of disease. Findings from this study further suggest some inequalities in financial toxicity between survivors and deaths reporting at 1-year post-diagnosis. The survivor group reported significantly less difficulties compared to the death group. However, this result did not remain statistically significant in multivariate model. In Korea, since 2004, the government has introduced a policy that decreases co-payment for cancer patients from 30% to 5% \[[@b34-crt-2018-426]\]. However, financial difficulties might occur even when the co-payment is not required or at low proportion \[[@b35-crt-2018-426]\]. Financial toxicity has been associated with not only worse survival as found in the current study and another \[[@b36-crt-2018-426]\], but also other factors such as lower patient satisfaction \[[@b37-crt-2018-426],[@b38-crt-2018-426]\] and worse compliance \[[@b39-crt-2018-426]\]. For the future, a deeper understanding of factors causing financial difficulties among cancer patients and how these impact on QOL as well as survival is warranted.

Our study had some limitations. The first limitation is the small number of observed deaths, which was expected because we only included early-stage BC patients in our cohort. Second, we did not have information on additional factors that could affect the QOL and survival outcomes, including the duration of treatment and recovery period or the patients' access to post-treatment support systems. Furthermore, generalizability of this study was limited as the study was conducted at a single institution. Missing data on BC cancer-related scales, including sexual functioning, were also considerable. Despite these limitations, our results have important implications in both clinical and research practices. HRQOL assessments after treatment may be useful as an early sign of patient deterioration and an indication of their survival. Intervention to improve role function and symptoms, including fatigue and nausea, could have the potential to improve survival outcomes.

Our analysis provides additional prognostic information for survival beyond that available from conventional factors. Besides medical-related symptoms, non-medical aspects, functional wellbeing, and future perspective in the first year after cancer diagnosis are significant prognostic factors for OS of BC. This suggests a possible avenue of intervention by maintaining or enhancing these functional supports for women soon after their BC diagnosis to improve disease outcomes. Regular follow-up and QOL measurements together with prompt intervention to enhance patient feelings and other associated factors might help to improve the long-term outcomes of patients.
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![Health-related quality of life (QOL) measured by QLQ-C30 functional scale after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the QOL mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.](crt-2018-426f2){#f2-crt-2018-426}

![Health-related quality of life (QOL) measured by QLQ-C30 symptom scale after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the quality of life (QOL) mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.](crt-2018-426f3){#f3-crt-2018-426}

![Health-related quality of life (QOL) measured by QLQ-BR23 after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the QOL mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.](crt-2018-426f4){#f4-crt-2018-426}

###### 

Demographic and clinical characteristics of the study population

  One-year post-diagnosis                                                        Total (n=206)   Survivor (n=174)   Death (n=32)   p-value
  ------------------------------------------------------------------------------ --------------- ------------------ -------------- ------------------------------------------------------
  **Demographic variable**                                                                                                         
   Age at diagnosis (yr)                                                                                                           
    20-44                                                                        71 (34.5)       60 (34.5)          11 (34.4)      0.321
    45-54                                                                        78 (37.9)       69 (39.7)          9 (28.1)       
    ≥ 55                                                                         57 (27.7)       45 (25.9)          12 (37.5)      
    Mean±SD                                                                      47.3±9.1        47.0±9.1           48.7 (9.7)     0.353^[a)](#tfn1-crt-2018-426){ref-type="table-fn"}^
   Education level at diagnosis                                                                                                    
    ≤ High school                                                                151 (73.7)      126 (72.4)         25 (80.7)      0.338
    ≥ University                                                                 54 (26.3)       48 (27.6)          6 (19.3)       
   Having religion                                                                                                                 
    No                                                                           52 (25.5)       48 (27.9)          4 (12.5)       0.066
    Yes                                                                          152 (74.5)      124 (72.1)         28 (87.5)      
   Job status                                                                                                                      
    No                                                                           117 (62.6)      99 (63.5)          18 (58.1)      0.571
    Yes                                                                          70 (37.4)       57 (36.5)          13 (41.9)      
   Monthly income (USD)                                                                                                            
    \< 2,000                                                                     81 (43.1)       68 (42.0)          13 (50.0)      0.443
    ≥ 2,000                                                                      107 (56.9)      94 (58.0)          13 (50.0)      
   Marital status                                                                                                                  
    Married                                                                      166 (81.0)      139 (80.4)         27 (84.4)      0.594
    Others                                                                       39 (19.0)       34 (19.7)          5 (15.6)       
   Drinking                                                                                                                        
    Yes                                                                          16 (8.3)        147 (90.7)         29 (96.7)      0.281
    No                                                                           176 (91.7)      15 (9.3)           1 (3.3)        
   Smoking                                                                                                                         
    Yes                                                                          3 (1.6)         161 (98.8)         28 (96.6)      0.374
    No                                                                           189 (98.4)      2 (1.2)            1 (3.5)        
  **Clinical characteristic**                                                                                                      
   Comorbidity status                                                                                                              
    No                                                                           130 (69.2)      116 (73.0)         14 (48.3)      0.008
    Yes                                                                          58 (30.9)       43 (27.0)          15 (51.7)      
   Radiotherapy                                                                                                                    
    No                                                                           43 (21.0)       36 (20.8)          7 (21.9)       0.892
    Yes                                                                          162 (79.0)      137 (79.2)         25 (78.1)      
   Duration of radiotherapy (day)                                                                                                  
    Mean±SD                                                                      46.7±21.5       45.5±11.2          53.8±51.0      0.093^[a)](#tfn1-crt-2018-426){ref-type="table-fn"}^
   Chemotherapy^[b)](#tfn2-crt-2018-426){ref-type="table-fn"}^                                                                     
    No                                                                           28 (13.7)       28 (16.2)          0              NA
    Yes                                                                          177 (86.3)      145 (83.8)         32 (100)       
   Duration of chemotherapy (day)                                                                                                  
    Mean±SD                                                                      116.0±42.8      113.8±36.3         125.6±64.6     0.161^[a)](#tfn1-crt-2018-426){ref-type="table-fn"}^
   Hormone therapy                                                                                                                 
    No                                                                           39 (18.9)       35 (20.1)          4 (12.5)       0.312
    Yes                                                                          167 (81.1)      139 (79.9)         28 (87.5)      
   Stage                                                                                                                           
    I-IIA                                                                        131 (63.6)      121 (69.5)         10 (31.3)      \< 0.001
    IIB-IV^[c)](#tfn3-crt-2018-426){ref-type="table-fn"}^                        75 (36.4)       53 (30.5)          22 (68.8)      
   Breast cancer tumor subtypes^[b)](#tfn2-crt-2018-426){ref-type="table-fn"}^                                                     
    ER/PR+, HER2+                                                                11 (5.4)        10 (5.8)           1 (3.2)        NA
    ER/PR+, HER2--                                                               156 (76.1)      129 (74.1)         27 (87.1)      
    ER/PR--, HER2+                                                               13 (6.3)        11 (6.3)           2 (6.5)        
    ER/PR--, HER2--                                                              25 (12.2)       24 (13.8)          1 (3.2)        

Values are presented as number (%) unless otherwise indicated. SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

p-value was obtained from the Kruskal-Wallis test,

NA, not available (due to small number of participant),

Five participants with stage IV.

Other p-values were obtained by Fisher\'s exact test.

###### 

HRQOL mean scores (QLQ-C30 and QLQ-BR23) at baseline and 1-year post-diagnosis

  QOL scale                             No. (n=206)   Total at 1 yr   Survivor   Death                                                     
  ------------------------------------- ------------- --------------- ---------- ------- ------ -------- ---------- ------ ------ -------- ----------
  Global health status                  206           66.1            1.4        55.2    67.4   12.2     \< 0.001   61.0   59.4   --1.6    0.906
  **EORTC QLQ-C30 Functional Scale**                                                                                                       
   Physical                             206           76.0            1.1        83.7    77.6   --6.2    \< 0.001   82.9   67.4   --15.5   \< 0.001
   Role                                 206           73.7            1.6        85.9    75.9   --10.0   \< 0.001   81.3   62.0   --19.3   0.001
   Emotional                            205           73.3            1.4        63.3    74.9   11.6     \< 0.001   63.7   64.7   1.0      0.511
   Cognitive                            205           74.3            1.3        81.7    75.0   --6.7    \< 0.001   82.3   70.3   --12.0   0.012
   Social                               201           71.1            1.9        75.1    72.6   --2.5    \< 0.001   74.7   63.0   --11.7   0.089
  **EORTC QLQ-C30 Symptom Scale**                                                                                                          
   Fatigue                              205           36.6            1.5        32.5    34.5   2.0      0.141      32.6   48.1   15.5     0.015
   Nausea and vomiting                  205           7.1             0.9        7.2     6.4    --0.8    0.509      8.6    10.9   2.3      0.247
   Pain                                 206           22.9            1.5        14.0    21.4   7.4      \< 0.001   16.7   31.3   14.6     0.042
   Dyspnea                              205           16.7            1.6        13.7    14.7   1.0      0.571      13.5   27.1   13.5     0.029
   Insomnia                             205           23.0            1.8        20.8    21.8   1.0      0.672      22.9   29.2   6.3      0.240
   Appetite loss                        205           15.5            1.7        19.1    14.7   --4.3    0.047      18.8   19.8   1.0      0.901
   Constipation                         204           18.3            1.7        14.8    16.5   1.6      0.327      22.6   28.1   5.5      0.379
   Diarrhea                             205           8.0             1.1        10.2    7.3    --2.9    0.046      10.4   11.5   1.0      0.948
   Financial difficulties               200           28.0            2.0        23.9    25.8   1.9      0.410      32.2   39.6   7.4      0.118
  **EORTC QLQ-BR23 Functional Scale**                                                                                                      
   Body image                           205           62.1            2.0        63.7    79.6   15.9     \< 0.001   77.7   53.6   --24.0   \< 0.001
   Sexual functioning                   181           24.7            1.8        25.3    21.8   --3.4    0.241      26.1   20.8   --5.3    0.212
   Sexual enjoyment                     68            41.2            3.3        42.2    37.5   --4.7    NA         50.0   33.3   --16.7   NA
   Future perspective                   205           42.0            2.0        43.2    37.4   --5.8    0.015      44.8   35.4   9.4      0.193
  **EORTC QLQ-BR23 Symptom Scale**                                                                                                         
   Systemic therapy                     206           28.4            1.5        16.6    25.1   --8.4    \< 0.001   22.1   30.2   --8.1    0.004
   Breast symptoms                      206           24.5            1.1        19.1    26.9   --7.9    0.203      21.2   36.5   --15.3   0.002
   Arm symptoms                         206           25.9            1.3        21.7    23.6   --1.9    \< 0.001   19.4   29.2   --9.8    0.050
   Upset by hair loss                   64            55.2            4.9        19.5    53.3   --33.8   0.005      20.5   61.9   --41.4   0.196

HRQOL, health-related quality of life; QOL, quality of life; SD, standard deviation; Base, Baseline; 1 yr, 1-year post-diagnosis; Diff., difference; NA, not available (due to small number of participant).

p-value was obtained from Wilcoxon signed-rank test to compare HRQOL scores measured at baseline with QOL scores measured at 1-year post-diagnosis, separately for survivors and deaths.

###### 

Association between HRQOL scores measured by QLQ-C30 and QLQ-BR23 at 1-year post-diagnosis and overall survival

  QOL scale                             Univariate model^[a)](#tfn5-crt-2018-426){ref-type="table-fn"}^   Adjusted model^[b)](#tfn6-crt-2018-426){ref-type="table-fn"}^          
  ------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------- ------ ----------------------------------------------------------------------------------------------------
  **Global health status/QOL**          0.84                                                              0.037                                                           0.77   0.047
  **EORTC QLQ-C30 Functional Scale**                                                                                                                                             
   Physical                             0.71                                                              0.001                                                           0.70   0.029^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Role                                 0.82                                                              0.002                                                           0.68   0.001^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Emotional                            0.82                                                              0.006                                                           0.72   0.012^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Cognitive                            0.89                                                              0.217                                                           0.76   0.058^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Social                               0.90                                                              0.076                                                           0.98   0.865^[d)](#tfn8-crt-2018-426){ref-type="table-fn"}^
  **EORTC QLQ-C30 Symptom Scale**                                                                                                                                                
   Fatigue                              1.26                                                              0.001                                                           1.34   0.006^[d)](#tfn8-crt-2018-426){ref-type="table-fn"}^
   Nausea and vomiting                  1.23                                                              0.046                                                           1.40   0.165^[d)](#tfn8-crt-2018-426){ref-type="table-fn"},[e)](#tfn9-crt-2018-426){ref-type="table-fn"}^
   Pain                                 1.18                                                              0.014                                                           1.16   0.118^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Dyspnea                              1.22                                                              0.002                                                           1.29   0.009^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Insomnia                             1.09                                                              0.156                                                           1.15   0.171
   Appetite loss                        1.09                                                              0.192                                                           1.24   0.036^[c)](#tfn7-crt-2018-426){ref-type="table-fn"},[d)](#tfn8-crt-2018-426){ref-type="table-fn"}^
   Constipation                         1.16                                                              0.010                                                           1.00   0.999
   Diarrhea                             1.13                                                              0.191                                                           1.24   0.091^[d)](#tfn8-crt-2018-426){ref-type="table-fn"}^
   Financial difficulties               1.14                                                              0.018                                                           1.03   0.776
  **EORTC QLQ-BR23 Functional Scale**                                                                                                                                            
   Body image                           0.90                                                              0.073                                                           0.95   0.560^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Sexual functioning                   0.93                                                              0.449                                                           0.83   0.182^[d)](#tfn8-crt-2018-426){ref-type="table-fn"}^
   Future perspective                   0.92                                                              0.188                                                           0.83   0.046
  **EORTC QLQ-BR23 Symptom Scale**                                                                                                                                               
   Systemic therapy SE                  1.19                                                              0.068                                                           1.33   0.126
   Breast symptoms                      1.12                                                              0.152                                                           0.98   0.919^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^
   Arm symptoms                         1.18                                                              0.023                                                           1.14   0.279^[c)](#tfn7-crt-2018-426){ref-type="table-fn"}^

HRQOL, health-related quality of life; QOL, quality of life; HR, hazard ratio; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire for Breast Cancer; SE, side effects.

Univariate Cox proportional hazard model, include score variable of each scale,

Multivariate Cox proportional hazard model, adjusted for age, stage at diagnosis, and baseline QOL scores. Sexual enjoyment and upset by hair lost scales were excluded due to small number of participants,

Additional adjusted factors: duration of radiotherapy,

Additional adjusted factors: comorbidity status,

Additional adjusted factors: education level and job status.
